Neurologist Dr David Dodick and gynecologist Dr Elizabeth Poynor argue that menopause should be understood as a neurological and cardiometabolic transition rather than a strictly reproductive one. Fluctuating estrogen alters brain glucose utilization and mitochondrial function while shifting fat distribution toward visceral stores and increasing insulin resistance, creating converging risks for cognition and cardiovascular health. Symptoms commonly dismissed as inevitable — brain fog, disrupted sleep, worsening migraine — may instead be early indicators of that transition.
Key Points
- Estrogen supports brain glucose use and mitochondrial energy production
- Migraine escalation in perimenopause signals broader hormonal transition
- Visceral fat, muscle loss and insulin resistance compound brain aging
Longevity Analysis
Midlife hormonal change reframes several complaints usually filed under normal aging as interpretable data. Brain fog, temperature dysregulation and fragmented sleep trace back to estrogen's role in hypothalamic regulation and cellular energy production, and reading them correctly opens a window for intervention before cardiometabolic risk consolidates. The convergence Dodick describes — aging brain, rising cardiovascular risk, declining estrogen — argues for assessment and action during perimenopause rather than after, when muscle mass, insulin sensitivity and vascular health are still responsive.
Original published by Longevity.Technology, by Kyle Umipig.